ArticleContemporary clinical trials2025
Protocol for a randomized clinical trial to evaluate the effectiveness of a technology-assisted motivational interviewing (TAMI) chatbot on smoking cessation.
Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06713603 (Technology Assisted Motivational Interviewing Randomized Controlled Trial), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Technology Assisted Motivational Interviewing Randomized Controlled Trial
Who cites it
1 citing paper in PubMed.
- Social Media Support Groups for Youth Nicotine Vaping Cessation: An RCT.American journal of preventive medicine · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe current project builds on our successful pilot work to develop a Technology-Assisted Motivational Interviewing (TAMI) chatbot and tobacco smoking cessation coach. TAMI is a highly scalable and easily accessible digital-coaching intervention that promotes readiness to change, provides compelling and accessible smoking cessation tools, and develops a tailored quit plan addressing social barriers to treatment initiation and sustainment.
methodsThe TAMI chatbot and associated digital architecture were optimized prior to the RCT using generative AI and incorporating feedback from both patients and experts. The resulting "TAMI 2.0" to be used in the RCT further supports smoking cessation by adding a nested, second chatbot that delivers education about evidence-based cessation tools, and a third nested chatbot that builds patient self-efficacy. The effectiveness of TAMI 2.0 will be determined by a 6-month, parallel 2-arm RCT comparing TAMI 2.0 to enhanced usual care. Adults who smoke (Target N = 440) recruited from primary care clinics will be randomized to (1) TAMI 2.0 or (2) usual care (UC). The primary outcome will be biochemically verified 7-day point prevalence abstinence from tobacco at 6 months with a secondary, self-reported, timepoint at 3 months. Other outcomes will include changes in readiness for cessation, smoking reduction, cessation outcome expectancies, smoking self-efficacy, and treatment initiation and sustainment.
conclusionsIf TAMI 2.0 is found to be an effective smoking cessation tool, this fully automated, patient-centered chatbot could be scaled to all communities greatly improving reach and access. NCT# NCT06713603.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.